Last edition
News about "phase 3 trial"
AstraZeneca Reports Positive Phase 3 Results for Tozorakimab in COPD
AstraZeneca’s Phase 3 OBERON and TITANIA trials showed that tozorakimab reduced moderate-to-severe COPD exacerbations across broad patient populations, including different blood eosinophil levels and smoking statuses.
Phase 3 Trial | 10/09/2026 | By News Bureau
Hansoh Pharma Reports Positive Phase 3 Results for Ris-Rez in China
Hansoh Pharma reported positive phase 3 results for Ris-Rez in China, while GSK advances development across lung cancer, prostate cancer and other solid tumors.
Phase 3 Trial | 31/07/2026 | By News Bureau
AstraZeneca, Ionis' Wainua Misses Phase 3 Primary Endpoint in ATTR-CM Trial
AstraZeneca and Ionis reported that Wainua (eplontersen) missed the primary endpoint in the phase 3 CARDIO-TTRansform trial for ATTR-CM, while maintaining a consistent safety profile.
Phase 3 Trial | 10/07/2026 | By News Bureau | 124
Viatris Reports Positive Phase 3 Results for VR-205 in IgA Nephropathy in Japan
Viatris reported positive Phase 3 results for VR-205 in Japanese adults with primary IgA nephropathy and plans to submit a New Drug Application (NDA) in Japan by the end of 2026.
Phase 3 Trial | 01/07/2026 | By News Bureau | 277
US Approves TRUQAP for PTEN-Deficient Metastatic Prostate Cancer
TRUQAP (capivasertib) has been approved in the US as the first targeted treatment for PTEN-deficient metastatic Hormone-Sensitive Prostate Cancer (mHSPC). The approval is supported by phase 3 CAPItello-281 data showing a 19 percent reduction in the risk of disease progression or death.
Phase 3 Trial | 15/06/2026 | By News Bureau | 110
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy